PBRM1 and renal cell carcinoma: To assess the impact of PBAF complex mutations in non-RCC cohorts treated with ICB profiled with MSK-IMPACT, we restricted our analysis to 11 tumor types with at least 50 patients and at least 5 patients with PBRM1 or ARID2 mutations (n = 2936).